Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Single Ascending Dose of HRS-2162 in Healthy Subjects — Stella

Home/Reversal of Neuromuscular Blockade/A Single Ascending Dose of HRS-2162 in Healthy Subjects

View on ClinicalTrials.gov

Recruiting

Back to Reversal of Neuromuscular Blockade trials

A Single Ascending Dose of HRS-2162 in Healthy Subjects

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Sichuan Academy of Medical Sciences &Sichuan Provincial People's Hospital, Chengdu, Sichuan

Key details

Phase

Early testing

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.

Enrollment target

~64 participants

Started

September 2025

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 45 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.